RSS   Newsletter   Contact   Advertise with us
Post Online Media

CTI BioPharma appoints Laurent Fischer as chairman

Laurent FischerCTI BioPharma, a biopharmaceutical company, announced that Laurent Fischer has been appointed its new chairman of the board.
Dr. Fischer has been a director at the company since July, 2017.

Dr. Fischer is currently Senior Vice President, Head of the Liver Therapeutic Area at Allergan following the acquisition of Tobira Therapeutics.

Dr. Fischer has served as a Senior Advisor on the Frazier Healthcare Partners' Life Sciences team since March 2017.

He was previously chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired by Sillajen.

Dr. Fischer was co-founder, president and CEO of Ocera Therapeutics and held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology.

Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

 

 LATEST MOVES FROM Washington 


 
 

POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.